Nuria Cano-Adamuz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nuria Cano-Adamuz has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Iñigo Azcoitia
Departamento de Biología Celular, Facultad de Biología, Universidad Complutense de Madrid, E-28040 Madrid, Spain
2 shared publications - Pablo Mendez
Instituto Cajal (CSIC), Madrid, Spain
2 shared publications - Alba González-Alonso
Department of Experimental Medicine Universitat de Lleida Lleida Spain
1 shared publication - Alberto Rodríguez-Fernández
Instituto Cajal (CSIC), Madrid, Spain
1 shared publication - Alberto Sanchez-Aguilera
Instituto Cajal (CSIC), Madrid, Spain
1 shared publication - Alicia Hernández-Vivanco
Instituto Cajal (CSIC), Madrid, Spain
1 shared publication
Latest Publications
- Open Access
Improved myelin clearance and cognitive outcomes after TBI in female mice are mediated by ovarian steroids and sex chromosomes
Traumatic brain injury (TBI) causes sex-specific memory deficits, yet the underlying mechanisms are not fully understood. Using a mouse TBI model, we investigated the role of reactive astrocytes in sex-specific outcome. TBI provoked long-term contextual memory impairment in males and ovariectomized females, but not in intact females. The synthetic steroid tibolone preserved memory and cFos+ neuronal density in the hippocampus of ovariectomized females. Hormone deprivation upregulated astrocytic GFAP and S100B, reduced Homer1, and impaired myelin phagocytosis by astrocytes in females. These effects were counteracted by tibolone. In Four-Core-Genotype mice, memory loss correlated with reduced astrocytic myelin uptake and neuronal activity in XX males and XY female animals. Astrocyte transplantation showed that female astrocytes exhibit superior myelin clearance capacity, especially in female brain environments, though they outperform male astrocytes in both sex contexts. These findings identify astrocyte-mediated myelin phagocytosis as a key mechanism for memory preservation after TBI, governed by both hormonal and chromosomal sex factors.
Open AccessImproved myelin clearance and cognitive outcomes after TBI in female mice are mediated by ovarian steroids and sex chromosomes
Traumatic brain injury (TBI) causes sex-specific memory deficits, yet the underlying mechanisms are not fully understood. Using a mouse TBI model, we investigated the role of reactive astrocytes in sex-specific outcome. TBI provoked long-term contextual memory impairment in males and ovariectomized females, but not in intact females. The synthetic steroid tibolone preserved memory and cFos+ neuronal density in the hippocampus of ovariectomized females. Hormone deprivation upregulated astrocytic GFAP and S100B, reduced Homer1, and impaired myelin phagocytosis by astrocytes in females. These effects were counteracted by tibolone. In Four-Core-Genotype mice, memory loss correlated with reduced astrocytic myelin uptake and neuronal activity in XX males and XY female animals. Astrocyte transplantation showed that female astrocytes exhibit superior myelin clearance capacity, especially in female brain environments, though they outperform male astrocytes in both sex contexts. These findings identify astrocyte-mediated myelin phagocytosis as a key mechanism for memory preservation after TBI, governed by both hormonal and chromosomal sex factors.
- Open Access
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S822
POSE TRACKING-BASED FREEZING DETECTION REVEALS THE DEPENDENCE OF FEAR RESPONSE GENERALIZATION ON LEARNING CONDITIONS
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S822
Open AccessPOSE TRACKING-BASED FREEZING DETECTION REVEALS THE DEPENDENCE OF FEAR RESPONSE GENERALIZATION ON LEARNING CONDITIONS
- Open Access
- 7 July 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-14
Sex-specific regulation of inhibition and network activity by local aromatase in the mouse hippocampus
Cognitive function relies on a balanced interplay between excitatory and inhibitory neurons (INs), but the impact of estradiol on IN function is not fully understood. Here, we characterize the regulation of hippocampal INs by aromatase, the enzyme responsible for estradiol synthesis, using a combination of molecular, genetic, functional and behavioral tools. The results show that CA1 parvalbumin-expressing INs (PV-INs) contribute to brain estradiol synthesis. Brain aromatase regulates synaptic inhibition through a mechanism that involves modification of perineuronal nets enwrapping PV-INs. In the female brain, aromatase modulates PV-INs activity, the dynamics of network oscillations and hippocampal-dependent memory. Aromatase regulation of PV-INs and inhibitory synapses is determined by the gonads and independent of sex chromosomes. These results suggest PV-INs are mediators of estrogenic regulation of behaviorally-relevant activity.
- 7 July 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-14
Open AccessSex-specific regulation of inhibition and network activity by local aromatase in the mouse hippocampus
Cognitive function relies on a balanced interplay between excitatory and inhibitory neurons (INs), but the impact of estradiol on IN function is not fully understood. Here, we characterize the regulation of hippocampal INs by aromatase, the enzyme responsible for estradiol synthesis, using a combination of molecular, genetic, functional and behavioral tools. The results show that CA1 parvalbumin-expressing INs (PV-INs) contribute to brain estradiol synthesis. Brain aromatase regulates synaptic inhibition through a mechanism that involves modification of perineuronal nets enwrapping PV-INs. In the female brain, aromatase modulates PV-INs activity, the dynamics of network oscillations and hippocampal-dependent memory. Aromatase regulation of PV-INs and inhibitory synapses is determined by the gonads and independent of sex chromosomes. These results suggest PV-INs are mediators of estrogenic regulation of behaviorally-relevant activity.
- Open Access
- 20 January 2020
- Published by Georg Thieme Verlag KG in Planta Medica International Open
- Vol. 7 (01) , e1-e11
Inhibition of HIF-1α through Suppression of NF-κB Activation by Compounds Isolated from Senecio graveolens
One of the characteristics of cancer is that the lack of oxygen in the cancer cells triggers changes in their gene expression. This hypoxia activates hypoxia-inducible factor 1-alpha and this in turn sets in motion the whole family of important angiogenic genes for the tumour. Hypoxia-inducible factor 1-alpha therefore increases the density and vascular permeability within the tumours, facilitating their rapid growth and, later, the metastasis. Senecio graveolens is a South American medicinal plant commonly used for mountain sickness (lack of adaptation of the organism to hypoxia). Additionally, pharmacological studies showed that its alcoholic extracts have cytotoxic properties. This research aimed to perform a guided phytochemical study of S. graveolens to identify compounds capable of inhibiting hypoxia-inducible factor 1-alpha through suppression of nuclear factor kappa-light-chain-enhancer of activated B cell activation. The isolation led to the characterisation of phanurane (1), damsine (2), and scoparone (3), first reported in the S. graveolens species. Phanurane (1 ) showed inhibitory activity of hypoxia-inducible factor 1-alpha on the cancer cell lines U-373 MG (IC50=20.66±0.04 μM), A549 (IC50=25.80±0.04 μM), Hep G2 (IC50=29.21±0.03 μM), and Caco-2 (IC50=38.58±0.02 μM). Damsine (2) hypoxia-inducible factor 1-alpha displayed inhibitory activity of hypoxia-inducible factor 1-alpha on the cancer cell lines U-373 MG (IC50=2.29±0.07 μM), A549 (IC50=4.13±0.04 μM), Hep G2 (IC50=6.40±0.03 μM), and Caco-2 (IC50=9.80±0.04 μM). Finally, scoparone (3) displayed inhibitory activity of hypoxia-inducible factor 1-alpha on the cancer cell lines U-373 MG (IC50=15.22±0.01 μM), A549 (IC50=17.47±0.02 μM), Hep G2 (IC50=18.26±0.06 μM), and Caco-2 (IC50=19.75±0.04 μM). In addition, phanurane (1 ) displayed inhibitory activity over nuclear factor kappa-light-chain-enhancer of activated B cells on cancer cell lines U-373 MG (IC50=7.13±0.03 μM), A549 (IC50=8.64±0.03 μM), Hep G2 (IC50=8.87±0.04 μM), and Caco-2 (IC50=15.11±0.01 μM). Likewise, damsine (2) showed inhibitory activity over nuclear factor kappa-light-chain-enhancer of activated B cells on cancer cell lines U-373 MG (IC50=2.28±0.01 μM), A549 (IC50=3.79±0.02 μM), Hep G2 (IC50=3.98±0.05 μM), and Caco-2 (IC50=6.41±0.02 μM). Lastly, scoparone (3) displayed inhibitory activity of nuclear factor kappa-light-chain-enhancer of activated B cells on cancer cell lines U-373 MG (IC50=3.62±0.06 μM), A549 (IC50=4.48±0.03 μM), Hep G2 (IC50=5.25±0.01 μM), and Caco-2 (IC50=11.90±0.02 μM). This study corroborates the cytotoxic activity of the isolated compounds through the inhibition of hypoxia-inducible factor 1-alpha as well as its modulator nuclear factor kappa-light-chain-enhancer of activated B cells.
- 20 January 2020
- Published by Georg Thieme Verlag KG in Planta Medica International Open
- Vol. 7 (01) , e1-e11
Open AccessInhibition of HIF-1α through Suppression of NF-κB Activation by Compounds Isolated from Senecio graveolens
One of the characteristics of cancer is that the lack of oxygen in the cancer cells triggers changes in their gene expression. This hypoxia activates hypoxia-inducible factor 1-alpha and this in turn sets in motion the whole family of important angiogenic genes for the tumour. Hypoxia-inducible factor 1-alpha therefore increases the density and vascular permeability within the tumours, facilitating their rapid growth and, later, the metastasis. Senecio graveolens is a South American medicinal plant commonly used for mountain sickness (lack of adaptation of the organism to hypoxia). Additionally, pharmacological studies showed that its alcoholic extracts have cytotoxic properties. This research aimed to perform a guided phytochemical study of S. graveolens to identify compounds capable of inhibiting hypoxia-inducible factor 1-alpha through suppression of nuclear factor kappa-light-chain-enhancer of activated B cell activation. The isolation led to the characterisation of phanurane (1), damsine (2), and scoparone (3), first reported in the S. graveolens species. Phanurane (1 ) showed inhibitory activity of hypoxia-inducible factor 1-alpha on the cancer cell lines U-373 MG (IC50=20.66±0.04 μM), A549 (IC50=25.80±0.04 μM), Hep G2 (IC50=29.21±0.03 μM), and Caco-2 (IC50=38.58±0.02 μM). Damsine (2) hypoxia-inducible factor 1-alpha displayed inhibitory activity of hypoxia-inducible factor 1-alpha on the cancer cell lines U-373 MG (IC50=2.29±0.07 μM), A549 (IC50=4.13±0.04 μM), Hep G2 (IC50=6.40±0.03 μM), and Caco-2 (IC50=9.80±0.04 μM). Finally, scoparone (3) displayed inhibitory activity of hypoxia-inducible factor 1-alpha on the cancer cell lines U-373 MG (IC50=15.22±0.01 μM), A549 (IC50=17.47±0.02 μM), Hep G2 (IC50=18.26±0.06 μM), and Caco-2 (IC50=19.75±0.04 μM). In addition, phanurane (1 ) displayed inhibitory activity over nuclear factor kappa-light-chain-enhancer of activated B cells on cancer cell lines U-373 MG (IC50=7.13±0.03 μM), A549 (IC50=8.64±0.03 μM), Hep G2 (IC50=8.87±0.04 μM), and Caco-2 (IC50=15.11±0.01 μM). Likewise, damsine (2) showed inhibitory activity over nuclear factor kappa-light-chain-enhancer of activated B cells on cancer cell lines U-373 MG (IC50=2.28±0.01 μM), A549 (IC50=3.79±0.02 μM), Hep G2 (IC50=3.98±0.05 μM), and Caco-2 (IC50=6.41±0.02 μM). Lastly, scoparone (3) displayed inhibitory activity of nuclear factor kappa-light-chain-enhancer of activated B cells on cancer cell lines U-373 MG (IC50=3.62±0.06 μM), A549 (IC50=4.48±0.03 μM), Hep G2 (IC50=5.25±0.01 μM), and Caco-2 (IC50=11.90±0.02 μM). This study corroborates the cytotoxic activity of the isolated compounds through the inhibition of hypoxia-inducible factor 1-alpha as well as its modulator nuclear factor kappa-light-chain-enhancer of activated B cells.